Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.36 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | CCR1 | P32246 | 2/20 | 0.35 |
| ▸ | CCR5 | P51681 | 2/20 | 0.35 |
| ▸ | CCR8 | P51685 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13705702 | 1.00 | CYP1A2 (0.38) | CYP1A2CYP2C9CYP2C19SLC5A2P4HTM | |
| SCHEMBL19135074 | 1.00 | CYP1A2 (0.38) | CYP1A2CYP2C9CYP2C19SLC5A2P4HTM | |
| SCHEMBL14533667 | 0.79 | PIM1 (0.35) | SLC5A2LMNAHIF1ATP53HTT | |
| SCHEMBL14507291 | 0.79 | PIM1 (0.35) | SLC5A2LMNAHIF1ATP53HTT | |
| SCHEMBL15129319 | 0.78 | DRD2 (0.41) | SLC5A2LMNATP53HTTSMN1; SMN2 | |
| SCHEMBL14391672 | 0.78 | DRD2 (0.41) | SLC5A2LMNATP53HTTSMN1; SMN2 | |
| SCHEMBL10183381 | 0.78 | DRD2 (0.41) | SLC5A2LMNATP53HTTSMN1; SMN2 | |
| SCHEMBL19135285 | 0.78 | DRD2 (0.41) | SLC5A2LMNATP53HTTSMN1; SMN2 | |
| SCHEMBL14533671 | 0.76 | CYP2A6 (0.58) | POLBSMN1; SMN2CYP2A6 | |
| SCHEMBL5878277 | 0.76 | CYP2A6 (0.58) | POLBSMN1; SMN2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220403377-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11530408-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11312957-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20200255833-A1 | THERAPEUTIC COMPOSITIONS | BANK OF AMERICA, N.A. | 2020-08-13 | — | — | US | disclosed |
| US-10676740-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-10669544-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190345498-A1 | MODIFIED iRNA AGENTS | BANK OF AMERICA, N.A. | 2019-11-14 | — | — | US | disclosed |
| US-20190264207-A1 | THERAPEUTIC COMPOSITIONS | BANK OF AMERICA, N.A. | 2019-08-29 | — | — | US | disclosed |
| US-10273477-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20170283801-A1 | THERAPEUTIC COMPOSITIONS | BANK OF AMERICA, N.A. | 2017-10-05 | — | — | US | disclosed |
| US-20110054160-A1 | THERAPEUTIC COMPOSITIONS | ALNYLAM PHARMACEUTICALS (US) | 2011-03-03 | — | — | US | disclosed |
| US-20100292455-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292455-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100240881-A1 | THERAPEUTIC COMPOSITIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240881-A1 | THERAPEUTIC COMPOSITIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| EP-1605978-B1 | THERAPEUTIC COMPOSITIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2010-09-01 | — | — | EP | disclosed |
| US-7745608-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745608-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20070275914-A1 | Therapeutic Compositions | BANK OF AMERICA, N.A. | 2007-11-29 | — | — | US | disclosed |
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273477-B2 | Therapeutic compositions | SNRPE, HNRNPH3, RNASE1 | CYP1A2 4881/4885CYP2C9 4884/4885CYP2C19 4882/4885 |
| US-20220403377-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | CYP1A2 3847/4885CYP2C9 4443/4885CYP2C19 4752/4885 |
| US-20110054160-A1 | THERAPEUTIC COMPOSITIONS | SNRPE, HNRNPH3, RNASE1 | CYP1A2 4881/4885CYP2C9 4884/4885CYP2C19 4882/4885 |
| US-20190345498-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | CYP1A2 3847/4885CYP2C9 4443/4885CYP2C19 4752/4885 |
| US-20100292455-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | CYP1A2 3847/4885CYP2C9 4443/4885CYP2C19 4752/4885 |
| US-20190264207-A1 | THERAPEUTIC COMPOSITIONS | SNRPE, HNRNPH3, RNASE1 | CYP1A2 4881/4885CYP2C9 4884/4885CYP2C19 4882/4885 |
| US-20200255833-A1 | THERAPEUTIC COMPOSITIONS | SNRPE, HNRNPH3, RNASE1 | CYP1A2 4881/4885CYP2C9 4884/4885CYP2C19 4882/4885 |
| US-20070275914-A1 | Therapeutic Compositions | AGO2, EXOSC5, RNASE1 | CYP1A2 4371/4885CYP2C9 4650/4885CYP2C19 4431/4885 |
| US-20100240881-A1 | THERAPEUTIC COMPOSITIONS | SNRPE, HNRNPH3, RNASE1 | CYP1A2 4881/4885CYP2C9 4884/4885CYP2C19 4882/4885 |
| US-10676740-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | CYP1A2 3847/4885CYP2C9 4443/4885CYP2C19 4752/4885 |
| US-11530408-B2 | Therapeutic compositions | SNRPE, HNRNPH3, RNASE1 | CYP1A2 4881/4885CYP2C9 4884/4885CYP2C19 4882/4885 |
| US-20170283801-A1 | THERAPEUTIC COMPOSITIONS | SNRPE, HNRNPH3, RNASE1 | CYP1A2 4881/4885CYP2C9 4884/4885CYP2C19 4882/4885 |
| US-10669544-B2 | Therapeutic compositions | SNRPE, HNRNPH3, RNASE1 | CYP1A2 4881/4885CYP2C9 4884/4885CYP2C19 4882/4885 |
| US-11312957-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | CYP1A2 3847/4885CYP2C9 4443/4885CYP2C19 4752/4885 |
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | CYP1A2 2684/4885CYP2C9 3809/4885CYP2C19 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.